AvenCell Europe GmbH

4 trials 3 recruiting Commercial sponsor Merged from 2 name variants

Filter these 4 trials by condition, phase, country and more.

Open in Search →

4 Registered trials

3 Recruiting

1 Completed trials

2 Countries active

1 Unique IMPs

100% Results reported

Phase I

Phase I (Other)

Phase I (FiH)

Phase I: 2 Phase I (Other): 1 Phase I (FiH): 1

100%

1 of 1 completed trials have published summary results (EU CTR Article 37 — 12-month obligation).

View full Transparency Scoreboard →

Top IMPs

ALLO-QUADCAR01-T 1

All trials

4 total

Long-Term Follow-up of AvenCell-Sponsored CAR-T Cell Clinical Trials Recruiting

2025-521717-67-00 Phase I (Other) 1 country
QUADvance: Advancing Allogeneic Quad-CAR01-T Therapy in Hard-to-Treat B-Cell Cancers Recruiting

2025-521735-36-00 Phase I (FiH) 1 country ALLO-QUADCAR01-T
Phase 1 Study of Allo-RevCAR01-T-CD123 in Patients With Selected CD123 Positive Hematologic Malignancies Recruiting

2022-501797-19-00 Phase I 2 countries
Phase 1 Study of UniCAR02-T-CD123 in Patients With Selected CD123 Positive Hematologic Malignancies Ended

2024-515827-12-00 Phase I 2 countries

Showing 1–4 of 4 trials

← All sponsors A–Z